查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1609134

奈米医学市场：按分子类型、形态、应用和适应症分类 - 全球预测 2025-2030

Nanomedicine Market by Molecule Type (Nanodevices, Nanoparticles, Nanoshells), Modality (Diagnostics, Treatment), Application, Indication - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年奈米医学市场价值为2062.5亿美元，预计到2024年将达到2273.7亿美元，复合年增长率为10.91%，到2030年将达到4258.8亿美元。

奈米医学奈米技术用于开发分子层面的医疗应用工具和治疗方法。这些包括药物传输、诊断、影像和再生医学。对奈米医学的需求源于对副作用较少的标靶治疗的需求，以解决使用传统方法无法有效治疗的复杂病症。其应用范围广泛，为先前未满足的医疗需求提供解决方案，包括提高癌症治疗的精确度、提高药物溶解度和组织工程。主要最终用途领域包括癌症治疗、心血管和神经系统疾病以及感染疾病。

主要市场统计
基准年[2023] 2062.5亿美元
预测年份 [2024] 2273.7亿美元
预测年份 [2030] 4258.8亿美元
复合年增长率（%） 10.91%

该市场是由技术创新、慢性病的增加以及政府和私营部门研究投资的增加所推动的。奈米技术的快速发展以及製药公司和研究机构之间的合作也极为重要。然而，研究成本上升、监管障碍和潜在毒性问题等挑战正在阻碍成长。严格的核准流程和研发的复杂性也是主要障碍。

市场上的机会已经成熟，可以根据个人的基因特征客製化个人化医疗。生物分解性奈米颗粒的探索以及透过超灵敏生物感测器增强诊断能力呈现出宝贵的前景。为了利用这些优势，促进学术界和工业界之间的合作并确保转化研究的资金非常重要。另一个有前景的领域是开发多功能奈米医学系统，将治疗和诊断功能整合到一个平台中。

为了实现业务成长，您应该专注于医疗保健需求和基础设施不断增长的地区，例如亚太地区和拉丁美洲。创新格局应优先考虑安全性和有效性，并纳入以患者为中心的策略。总体而言，市场格局正在扩大，但应对复杂的监管格局和技术需求需要战略远见和适应性创新。

市场动态：揭示快速发展的奈米医学市场的关键市场洞察

供需的动态交互作用正在改变奈米医学市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 慢性病的流行和有效治疗的需求
    • 利用奈米医学技术进行个人化医疗
    • 在体外诊断和体内成像的应用
  • 市场限制因素
    • 奈米药物的开发和商业化成本高昂
  • 市场机会
    • 新型奈米医学开发策略联盟
    • 奈米医学研究和开发的有利资金状况
  • 市场挑战
    • 可用的临床证据有限

波特五力：驾驭奈米医学市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解奈米医学市场的外部影响

外部宏观环境因素在塑造奈米医学市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解奈米医学市场的竞争状况

对奈米医学市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵奈米医学市场供应商绩效评估

FPNV定位矩阵是评估奈米医学市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了奈米医学市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，奈米医学市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性病的流行和有效治疗的需求
      • 奈米医学技术在个人化医疗的应用
      • 在体外诊断和体内成像的应用
    • 抑制因素
      • 奈米药物的开发和商业化成本高昂
    • 机会
      • 奈米医学新开发策略联盟
      • 奈米医学研究和开发的有利资金筹措环境
    • 任务
      • 临床证据有限
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章以分子类型分類的奈米医学市场

  • 奈米装置
  • 奈米粒子
    • 树状聚合物
    • 水凝胶奈米颗粒
    • 无机奈米粒子
    • 脂质体
    • 金属和金属氧化物奈米粒子
    • 聚合物和聚合物药物缀合物
  • 奈米壳
  • 奈米管

第七章 奈米医学市场：依形式

  • 诊断
  • 治疗

第八章奈米医学市场：依应用分类

  • 诊断影像
  • 药物输送
  • 植入
  • 再生医学
  • 疫苗

第九章 奈米医学市场（按适应症）

  • 临床心臟病学
  • 临床肿瘤学
  • 免疫学
  • 感染疾病
  • 神经病学
  • 眼科
  • 整形外科
  • 泌尿系统

第十章美洲奈米医学市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区奈米医学市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的奈米医学市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AMAG Pharmaceuticals, Inc.
  • Amgen Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • Bausch Health Companies Inc.
  • Bayer Healthcare
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eisai Co Ltd
  • F. Hoffmann-La Roche AG
  • Galen Ltd
  • General Electric Company
  • Gilead Sciences, Inc.
  • Ipsen SA
  • Jazz Pharmaceuticals plc
  • Lantheus Holdings, Inc.
  • Leadient BioSciences Inc.
  • Mallinckrodt Pharmaceuticals
  • Merck & Co., Inc.
  • Nano spectra Biosciences, Inc.
  • Novo Nordisk A/S
  • OSARTIS GmbH
  • Pacira BioSciences Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Taiwan Liposome Company, Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceuticals Ltd.
  • UCB SA
  • Zimmer Biomet Holdings, Inc.
Product Code: MRR-C002B1C9955D

The Nanomedicine Market was valued at USD 206.25 billion in 2023, expected to reach USD 227.37 billion in 2024, and is projected to grow at a CAGR of 10.91%, to USD 425.88 billion by 2030.

Nanomedicine harnesses nanotechnology's advancements in developing tools and treatments at the molecular level for medical applications. It covers drug delivery, diagnostics, imaging, and regenerative medicine. The necessity of nanomedicine arises from the demand for targeted therapies with minimal side effects, addressing complex conditions that traditional methods can't effectively treat. Its application is vast, offering enhanced precision in cancer therapy, improved drug solubility, and tissue engineering, providing solutions for previously unmet medical needs. Key end-use areas include cancer treatment, cardiovascular and neurological disorders, and infectious diseases.

KEY MARKET STATISTICS
Base Year [2023] USD 206.25 billion
Estimated Year [2024] USD 227.37 billion
Forecast Year [2030] USD 425.88 billion
CAGR (%) 10.91%

The market is driven by technological innovations, the rising prevalence of chronic diseases, and increasing government and private sector investments in research. Rapid advancements in nanotechnology and collaborations between pharmaceuticals and research institutions are also pivotal. However, challenges such as high costs of research, regulatory hurdles, and potential toxicity issues impede growth. The strict approval process and R&D complexity also pose significant barriers.

Opportunities within the market are ripe in personalized medicine, where nanomedicine can be tailored to individual genetic profiles. Exploring biodegradable nanoparticles and enhancing diagnostic capabilities with ultra-sensitive biosensors present valuable prospects. To capitalize on these, fostering collaborations between academia and industry and securing funding for translational research are crucial. Another promising area is the development of multifunctional nanomedicine systems that combine therapeutic and diagnostic functions into a single platform.

For business growth, focus should be on regions with growing healthcare needs and infrastructure, like Asia-Pacific and Latin America. The innovation landscape should prioritize safety and efficacy, embedding patient-centric strategies. Overall, while the nanomedicine market is poised for expansive growth, navigating its complex regulatory landscape and technological demands will require strategic foresight and adaptive innovation.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Nanomedicine Market

The Nanomedicine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of chronic diseases and need for efficient treatment
    • Utilization of nanomedicine technology for personalized medicine
    • Applications in vitro diagnostics and in vivo imaging
  • Market Restraints
    • High cost of development and commercialization of nanomedicine
  • Market Opportunities
    • Strategic alliances for development of novel nanomedicine
    • Favorable funding landscape for research and development of nanomedicine
  • Market Challenges
    • Limited availability of clinical evidence

Porter's Five Forces: A Strategic Tool for Navigating the Nanomedicine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Nanomedicine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Nanomedicine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Nanomedicine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Nanomedicine Market

A detailed market share analysis in the Nanomedicine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Nanomedicine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Nanomedicine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Nanomedicine Market

A strategic analysis of the Nanomedicine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Nanomedicine Market, highlighting leading vendors and their innovative profiles. These include AMAG Pharmaceuticals, Inc., Amgen Inc., Arrowhead Pharmaceuticals, Inc., Bausch Health Companies Inc., Bayer Healthcare, Biogen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Eisai Co Ltd, F. Hoffmann-La Roche AG, Galen Ltd, General Electric Company, Gilead Sciences, Inc., Ipsen SA, Jazz Pharmaceuticals plc, Lantheus Holdings, Inc., Leadient BioSciences Inc., Mallinckrodt Pharmaceuticals, Merck & Co., Inc., Nano spectra Biosciences, Inc., Novo Nordisk A/S, OSARTIS GmbH, Pacira BioSciences Inc., Pfizer Inc., Sanofi S.A., Taiwan Liposome Company, Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Ltd., UCB SA, and Zimmer Biomet Holdings, Inc..

Market Segmentation & Coverage

This research report categorizes the Nanomedicine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Molecule Type, market is studied across Nanodevices, Nanoparticles, Nanoshells, and Nanotubes. The Nanoparticles is further studied across Dendrimers, Hydrogel Nanoparticles, Inorganic Nanoparticles, Liposomes, Metal & Metal Oxide Nanoparticles, and Polymers & Polymer Drug Conjugates.
  • Based on Modality, market is studied across Diagnostics and Treatment.
  • Based on Application, market is studied across Diagnostic Imaging, Drug Delivery, Implants, Regenerative Medicine, and Vaccines.
  • Based on Indication, market is studied across Clinical Cardiology, Clinical Oncology, Immunology, Infectious Diseases, Neurology, Ophthalmology, Orthopedics, and Urology.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of chronic diseases and need for efficient treatment
      • 5.1.1.2. Utilization of nanomedicine technology for personalized medicine
      • 5.1.1.3. Applications in vitro diagnostics and in vivo imaging
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of development and commercialization of nanomedicine
    • 5.1.3. Opportunities
      • 5.1.3.1. Strategic alliances for development of novel nanomedicine
      • 5.1.3.2. Favorable funding landscape for research and development of nanomedicine
    • 5.1.4. Challenges
      • 5.1.4.1. Limited availability of clinical evidence
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Nanomedicine Market, by Molecule Type

  • 6.1. Introduction
  • 6.2. Nanodevices
  • 6.3. Nanoparticles
    • 6.3.1. Dendrimers
    • 6.3.2. Hydrogel Nanoparticles
    • 6.3.3. Inorganic Nanoparticles
    • 6.3.4. Liposomes
    • 6.3.5. Metal & Metal Oxide Nanoparticles
    • 6.3.6. Polymers & Polymer Drug Conjugates
  • 6.4. Nanoshells
  • 6.5. Nanotubes

7. Nanomedicine Market, by Modality

  • 7.1. Introduction
  • 7.2. Diagnostics
  • 7.3. Treatment

8. Nanomedicine Market, by Application

  • 8.1. Introduction
  • 8.2. Diagnostic Imaging
  • 8.3. Drug Delivery
  • 8.4. Implants
  • 8.5. Regenerative Medicine
  • 8.6. Vaccines

9. Nanomedicine Market, by Indication

  • 9.1. Introduction
  • 9.2. Clinical Cardiology
  • 9.3. Clinical Oncology
  • 9.4. Immunology
  • 9.5. Infectious Diseases
  • 9.6. Neurology
  • 9.7. Ophthalmology
  • 9.8. Orthopedics
  • 9.9. Urology

10. Americas Nanomedicine Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Nanomedicine Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Nanomedicine Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AMAG Pharmaceuticals, Inc.
  • 2. Amgen Inc.
  • 3. Arrowhead Pharmaceuticals, Inc.
  • 4. Bausch Health Companies Inc.
  • 5. Bayer Healthcare
  • 6. Biogen Inc.
  • 7. Bristol-Myers Squibb Company
  • 8. Celgene Corporation
  • 9. Eisai Co Ltd
  • 10. F. Hoffmann-La Roche AG
  • 11. Galen Ltd
  • 12. General Electric Company
  • 13. Gilead Sciences, Inc.
  • 14. Ipsen SA
  • 15. Jazz Pharmaceuticals plc
  • 16. Lantheus Holdings, Inc.
  • 17. Leadient BioSciences Inc.
  • 18. Mallinckrodt Pharmaceuticals
  • 19. Merck & Co., Inc.
  • 20. Nano spectra Biosciences, Inc.
  • 21. Novo Nordisk A/S
  • 22. OSARTIS GmbH
  • 23. Pacira BioSciences Inc.
  • 24. Pfizer Inc.
  • 25. Sanofi S.A.
  • 26. Taiwan Liposome Company, Ltd.
  • 27. Takeda Pharmaceutical Company Limited
  • 28. Teva Pharmaceuticals Ltd.
  • 29. UCB SA
  • 30. Zimmer Biomet Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. NANOMEDICINE MARKET RESEARCH PROCESS
  • FIGURE 2. NANOMEDICINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NANOMEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NANOMEDICINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NANOMEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NANOMEDICINE MARKET SIZE, BY MODALITY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NANOMEDICINE MARKET SIZE, BY MODALITY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NANOMEDICINE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL NANOMEDICINE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL NANOMEDICINE MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL NANOMEDICINE MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS NANOMEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS NANOMEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES NANOMEDICINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES NANOMEDICINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC NANOMEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC NANOMEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NANOMEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NANOMEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. NANOMEDICINE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. NANOMEDICINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NANOMEDICINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NANOMEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NANOMEDICINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NANOMEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NANOMEDICINE MARKET DYNAMICS
  • TABLE 7. GLOBAL NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NANOMEDICINE MARKET SIZE, BY NANODEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NANOMEDICINE MARKET SIZE, BY DENDRIMERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NANOMEDICINE MARKET SIZE, BY HYDROGEL NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NANOMEDICINE MARKET SIZE, BY INORGANIC NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NANOMEDICINE MARKET SIZE, BY LIPOSOMES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NANOMEDICINE MARKET SIZE, BY METAL & METAL OXIDE NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NANOMEDICINE MARKET SIZE, BY POLYMERS & POLYMER DRUG CONJUGATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NANOMEDICINE MARKET SIZE, BY NANOSHELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NANOMEDICINE MARKET SIZE, BY NANOTUBES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NANOMEDICINE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL NANOMEDICINE MARKET SIZE, BY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL NANOMEDICINE MARKET SIZE, BY DIAGNOSTIC IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL NANOMEDICINE MARKET SIZE, BY DRUG DELIVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL NANOMEDICINE MARKET SIZE, BY IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL NANOMEDICINE MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL NANOMEDICINE MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL NANOMEDICINE MARKET SIZE, BY CLINICAL CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL NANOMEDICINE MARKET SIZE, BY CLINICAL ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL NANOMEDICINE MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL NANOMEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL NANOMEDICINE MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL NANOMEDICINE MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL NANOMEDICINE MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL NANOMEDICINE MARKET SIZE, BY UROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS NANOMEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES NANOMEDICINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC NANOMEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 83. CHINA NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. CHINA NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. INDIA NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 87. INDIA NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 88. INDIA NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. INDIA NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. INDONESIA NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. INDONESIA NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 92. INDONESIA NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 93. INDONESIA NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. INDONESIA NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. JAPAN NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. JAPAN NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 97. JAPAN NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 98. JAPAN NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. JAPAN NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. MALAYSIA NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. MALAYSIA NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 102. MALAYSIA NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 103. MALAYSIA NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. MALAYSIA NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. PHILIPPINES NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. PHILIPPINES NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 107. PHILIPPINES NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 108. PHILIPPINES NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. PHILIPPINES NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. SINGAPORE NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. SINGAPORE NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 112. SINGAPORE NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 113. SINGAPORE NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. SINGAPORE NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. SOUTH KOREA NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. SOUTH KOREA NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 117. SOUTH KOREA NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 118. SOUTH KOREA NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. SOUTH KOREA NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. TAIWAN NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. TAIWAN NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 122. TAIWAN NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 123. TAIWAN NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. TAIWAN NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. THAILAND NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. THAILAND NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 127. THAILAND NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 128. THAILAND NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. THAILAND NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. VIETNAM NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. VIETNAM NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 132. VIETNAM NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 133. VIETNAM NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. VIETNAM NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA NANOMEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 141. DENMARK NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. DENMARK NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 143. DENMARK NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 144. DENMARK NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. DENMARK NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. EGYPT NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. EGYPT NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 148. EGYPT NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 149. EGYPT NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. EGYPT NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. FINLAND NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. FINLAND NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 153. FINLAND NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 154. FINLAND NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. FINLAND NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 156. FRANCE NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. FRANCE NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 158. FRANCE NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 159. FRANCE NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. FRANCE NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. GERMANY NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. GERMANY NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 163. GERMANY NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 164. GERMANY NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. GERMANY NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 166. ISRAEL NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. ISRAEL NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 168. ISRAEL NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 169. ISRAEL NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. ISRAEL NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. ITALY NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. ITALY NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 173. ITALY NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 174. ITALY NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. ITALY NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. NETHERLANDS NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. NETHERLANDS NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 178. NETHERLANDS NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 179. NETHERLANDS NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. NETHERLANDS NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 181. NIGERIA NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. NIGERIA NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 183. NIGERIA NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 184. NIGERIA NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. NIGERIA NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. NORWAY NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. NORWAY NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 188. NORWAY NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 189. NORWAY NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. NORWAY NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 191. POLAND NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. POLAND NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 193. POLAND NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 194. POLAND NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 195. POLAND NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 196. QATAR NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. QATAR NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 198. QATAR NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 199. QATAR NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 200. QATAR NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 201. RUSSIA NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. RUSSIA NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 203. RUSSIA NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 204. RUSSIA NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 205. RUSSIA NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 206. SAUDI ARABIA NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SAUDI ARABIA NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 208. SAUDI ARABIA NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 209. SAUDI ARABIA NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 210. SAUDI ARABIA NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH AFRICA NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SOUTH AFRICA NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 213. SOUTH AFRICA NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 214. SOUTH AFRICA NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 215. SOUTH AFRICA NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 216. SPAIN NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. SPAIN NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 218. SPAIN NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 219. SPAIN NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 220. SPAIN NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 221. SWEDEN NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. SWEDEN NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 223. SWEDEN NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 224. SWEDEN NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 225. SWEDEN NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 226. SWITZERLAND NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. SWITZERLAND NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 228. SWITZERLAND NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 229. SWITZERLAND NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 230. SWITZERLAND NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 231. TURKEY NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. TURKEY NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 233. TURKEY NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 234. TURKEY NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 235. TURKEY NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED ARAB EMIRATES NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED ARAB EMIRATES NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED ARAB EMIRATES NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED ARAB EMIRATES NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED ARAB EMIRATES NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 241. UNITED KINGDOM NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. UNITED KINGDOM NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 243. UNITED KINGDOM NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 244. UNITED KINGDOM NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 245. UNITED KINGDOM NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 246. NANOMEDICINE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 247. NANOMEDICINE MARKET, FPNV POSITIONING MATRIX, 2023